Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ivan Borrello

Showing results (21-30 of 82) with videos related to

Pageof 9
Sort By:
Blood|July 29, 2010
A novel role of IL-17-producing lymphocytes in mediating lytic bone disease in multiple myelomaKimberly Noonan, Luigi Marchionni, Judy Anderson, et al.
Biorxiv : the Preprint Server for Biology|September 11, 2023
Tumor-Specific CD8<sup>+</sup> T Cells from the Bone Marrow Resist Exhaustion and Exhibit Increased Persistence in Tumor-Bearing Hosts as Compared to Tumor Infiltrating LymphocytesElizabeth M Zawidzka, Luca Biavati, Amy Thomas, et al.
Blood|December 8, 2007
Escape from suppression: tumor-specific effector cells outcompete regulatory T cells following stem-cell transplantationParia Mirmonsef, Gladys Tan, Gang Zhou, et al.
Hematology. American Society of Hematology. Education Program|November 10, 2001
New Developments in the Therapy of Acute Myelocytic LeukemiaNorbert C. Gorin, Elihu Estey, Richard J. Jones, et al.
Journal for Immunotherapy of Cancer|February 26, 2025
Tumor-specific CD8<sup>+</sup> T cells from the bone marrow resist exhaustion and exhibit increased persistence in tumor-bearing hosts as compared with tumor-infiltrating lymphocytesElizabeth M Zawidzka, Luca Biavati, Amy Thomas, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 14, 2012
Lenalidomide-induced immunomodulation in multiple myeloma: impact on vaccines and antitumor responsesKimberly Noonan, Lakshmi Rudraraju, Anna Ferguson, et al.
Blood|December 13, 2005
In vivo disruption of tolerogenic cross-presentation mechanisms uncovers an effective T-cell activation by B-cell lymphomas leading to antitumor immunityPedro Horna, Alex Cuenca, Fengdong Cheng, et al.
Plos One|December 1, 2017
Flow cytometric discrimination of seven lineage markers by using two fluorochromesFrancesco Boin, Maria Letizia Giardino Torchia, Ivan Borrello, et al.
The Journal of Experimental Medicine|November 15, 2006
Phosphodiesterase-5 inhibition augments endogenous antitumor immunity by reducing myeloid-derived suppressor cell functionPaolo Serafini, Kristen Meckel, Michael Kelso, et al.
Leukemia|July 1, 2020
A phase 1b study of dual PD-1 and CTLA-4 or KIR blockade in patients with relapsed/refractory lymphoid malignanciesPhilippe Armand, Alexander Lesokhin, Ivan Borrello, et al.
Pageof 9

Showing results (21-30 of 82) with videos related to

Sort By:
Pageof 9
Blood|July 29, 2010
A novel role of IL-17-producing lymphocytes in mediating lytic bone disease in multiple myelomaKimberly Noonan, Luigi Marchionni, Judy Anderson, et al.
Biorxiv : the Preprint Server for Biology|September 11, 2023
Tumor-Specific CD8<sup>+</sup> T Cells from the Bone Marrow Resist Exhaustion and Exhibit Increased Persistence in Tumor-Bearing Hosts as Compared to Tumor Infiltrating LymphocytesElizabeth M Zawidzka, Luca Biavati, Amy Thomas, et al.
Blood|December 8, 2007
Escape from suppression: tumor-specific effector cells outcompete regulatory T cells following stem-cell transplantationParia Mirmonsef, Gladys Tan, Gang Zhou, et al.
Hematology. American Society of Hematology. Education Program|November 10, 2001
New Developments in the Therapy of Acute Myelocytic LeukemiaNorbert C. Gorin, Elihu Estey, Richard J. Jones, et al.
Journal for Immunotherapy of Cancer|February 26, 2025
Tumor-specific CD8<sup>+</sup> T cells from the bone marrow resist exhaustion and exhibit increased persistence in tumor-bearing hosts as compared with tumor-infiltrating lymphocytesElizabeth M Zawidzka, Luca Biavati, Amy Thomas, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 14, 2012
Lenalidomide-induced immunomodulation in multiple myeloma: impact on vaccines and antitumor responsesKimberly Noonan, Lakshmi Rudraraju, Anna Ferguson, et al.
Blood|December 13, 2005
In vivo disruption of tolerogenic cross-presentation mechanisms uncovers an effective T-cell activation by B-cell lymphomas leading to antitumor immunityPedro Horna, Alex Cuenca, Fengdong Cheng, et al.
Plos One|December 1, 2017
Flow cytometric discrimination of seven lineage markers by using two fluorochromesFrancesco Boin, Maria Letizia Giardino Torchia, Ivan Borrello, et al.
The Journal of Experimental Medicine|November 15, 2006
Phosphodiesterase-5 inhibition augments endogenous antitumor immunity by reducing myeloid-derived suppressor cell functionPaolo Serafini, Kristen Meckel, Michael Kelso, et al.
Leukemia|July 1, 2020
A phase 1b study of dual PD-1 and CTLA-4 or KIR blockade in patients with relapsed/refractory lymphoid malignanciesPhilippe Armand, Alexander Lesokhin, Ivan Borrello, et al.
Pageof 9